![]() ![]() He concluded: “This comprehensive state of the art review of the field of catheter and surgical ablation of atrial fibrillation sets out standards for success rates, complication rates and clinical trial design. Professor Kuck said: “Patients with paroxysmal AF can now receive the primary treatment option straightaway, without any delay.” Previous recommendations said these patients should first receive an anti-arrhythmic drug and only proceed to catheter ablation if the drug failed. Professor Kuck said: “This should increase standardisation of trials and enable researchers, patients and organisation to compare success and complication rates more easily.”Īnother new feature in the 2012 document is a recommendation to perform catheter ablation in patients with paroxysmal AF and no or minimal underlying heart disease as a first line treatment. The minimum set of data that should be published is outlined, along with the endpoints and definitions that should be used. Standards are clearly set out for the design of clinical trials. “In this paper we clearly define the maximum overall complication rate so that patients can see if an institute is performing adequately.” “For an invasive procedure you want to know how successful it is but you also want to know how risky is it,” said Professor Kuck. Professor Kuck said: “If patients see that their doctor or institute is not achieving these minimum success rates, they can ask what the problem is.”Īlso for the first time, the authors state that the maximum overall complication rate should be in the region of 4.5%. At 12 months following the ablation procedure, the minimum acceptable success rates are 50% for paroxysmal AF, 40% for persistent AF and 30% for longstanding persistent AF. Success was defined as freedom from AF, atrial flutter (AFL) and atrial tachycardia (AT) and no antiarrhythmic drug therapy. The increase volume of data enabled the authors to calculate minimum acceptable success rates for the different types of AF for the first time. Newly analysed data on the long term outcome after successful ablation of longstanding persistent atrial fibrillation, shows that just 40-50% of patients remain free of recurrent AF after 5 years. But the long term outcome is not as good as we thought in 2007.” He added: “Data from randomised trials clearly indicate that catheter ablation is superior to any drug treatment for recurrences of atrial fibrillation and quality of life. “Significantly more data exist on techniques, success rates and complications of these new interventions, making this a more valid document compared to 2007,” said Professor Karl Heinz Kuck (Germany) president-elect of EHRA and co-chair of the task force that developed the document. Since the previous consensus document was published in 2007 catheter and surgical ablation of AF have become standard treatments and more randomised trials of ablation versus optimal drug therapy for AF have been conducted.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |